/RHHBY
RHHBY Stock - Roche Holding AG
Healthcare|Drug Manufacturers - GeneralOTC
$51.20+1.85%
+$0.93 (+1.85%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).59
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+4.5%upside
Target: $53.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RHHBY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$50.69 – $51.71
TARGET (TP)$53.50
STOP LOSS$47.10
RISK/REWARD1:0.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.17
52W High$51.49
52W Low$34.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $62.40B | $60.44B | $65.81B | $62.80B | $58.32B |
| Gross Profit | $46.11B | $44.84B | $44.44B | $43.10B | $41.97B |
| Gross Margin | 73.9% | 74.2% | 67.5% | 68.6% | 72.0% |
| Operating Income | $13.42B | $15.39B | $17.48B | $17.28B | $18.54B |
| Net Income | $8.28B | $11.50B | $12.42B | $13.93B | $14.29B |
| Net Margin | 13.3% | 19.0% | 18.9% | 22.2% | 24.5% |
| EPS | $1.30 | $1.80 | $1.94 | $2.05 | $2.09 |
Company Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
33%
Hold / Neutral
10
48%
Sell / Underperform
4
19%
Analyst Consensus🔴 Bearish
7 Bullish14 Neutral/Bearish
Price Targets
$39
Average Target
↓ 23.8% Downside
Now
$39
Low
$39
Average
$39
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | JP Morgan | Upgrade | Neutral | - |
| November 11th 2025 | Deutsche Bank | Upgrade | Hold | - |
| October 2nd 2025 | HSBC Securities | Upgrade | Buy | - |
| August 8th 2025 | Morgan Stanley | Downgrade | Underweight | $39 |
| April 28th 2025 | HSBC Securities | Downgrade | Hold | - |
| February 12th 2025 | Morgan Stanley | Initiation | Equal Weight | - |
| September 13th 2024 | Deutsche Bank | Downgrade | Sell | - |
| September 13th 2024 | BofA Securities | Upgrade | Buy | - |
| May 30th 2024 | Goldman | Initiation | Sell | - |
| May 17th 2024 | Deutsche Bank | Upgrade | Hold | - |
| March 4th 2024 | Argus | Downgrade | Hold | - |
| January 16th 2024 | UBS | Resumed | Neutral | - |
| January 16th 2024 | Morgan Stanley | Downgrade | Underweight | - |
| August 31st 2023 | BofA Securities | Downgrade | Neutral | - |
| July 14th 2023 | HSBC Securities | Initiation | Buy | - |
Earnings History & Surprises
RHHBYBeat Rate
19%
Last 16 quarters
Avg Surprise
-17.1%
EPS vs Estimate
Beats / Misses
3/13
Last 12 quarters
Latest EPS
$1.74
Q3 2025
EPS Surprise History
Q1 23
-4.2%
$1.14vs$1.19
Q2 23
-16.8%
$1.24vs$1.49
Q3 23
-2.7%
$1.45vs$1.49
Q4 23
-35.1%
$0.79vs$1.22
Q2 24
-16.2%
$1.09vs$1.30
Q4 24
-70.4%
$0.35vs$1.17
Q2 25
-55.2%
$0.73vs$1.62
Q3 25
+7.4%
$1.74vs$1.62
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 29, 2026 | — | — | — | — |
Q3 2025 | Jul 24, 2025 | $1.62 | $1.74 | +7.4% | ✓ BEAT |
Q2 2025 | Jun 30, 2025 | $1.62 | $0.73 | -55.2% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | $1.17 | $0.35 | -70.4% | ✗ MISS |
Q4 2024 | Oct 23, 2024 | — | — | — | — |
Q2 2024 | Jun 29, 2024 | $1.30 | $1.09 | -16.2% | ✗ MISS |
Q2 2024 | Apr 26, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | $1.22 | $0.79 | -35.1% | ✗ MISS |
Q4 2023 | Nov 29, 2023 | — | — | — | — |
Q3 2023 | Jul 27, 2023 | $1.49 | $1.45 | -2.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $1.49 | $1.24 | -16.8% | ✗ MISS |
Q1 2023 | Feb 2, 2023 | $1.19 | $1.14 | -4.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $1.19 | $0.66 | -44.7% | ✗ MISS |
Q3 2022 | Jul 21, 2022 | $1.41 | $1.52 | +7.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $1.41 | $1.37 | -2.8% | ✗ MISS |
Q1 2022 | Feb 3, 2022 | $1.32 | $1.26 | -4.5% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $1.32 | $0.98 | -26.0% | ✗ MISS |
Q3 2021 | Jul 22, 2021 | $1.38 | $1.44 | +4.3% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $1.38 | $1.22 | -11.6% | ✗ MISS |
Q1 2021 | Feb 1, 2021 | $1.24 | $1.21 | -2.4% | ✗ MISS |
Latest News
Genentech's Lunsumio VELO Gains FDA Approval As Subcutaneous Treatment Option For Relapsed Or Refractory Follicular Lymphoma
📈 PositiveBenzinga•Dec 22, 2025, 06:53 AM
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
'Novartis, Roche Near US Drug Price Deal in Easing of Swiss Trade Tensions'- Bloomberg
📈 PositiveBenzinga•Dec 17, 2025, 06:06 PM•Also:
FDA Expands Labels For Roche's HER2 Tests, Enabling Identification Of All HER2-Positive Metastatic Breast Cancer Patients Eligible For ENHERTU
📈 PositiveBenzinga•Dec 15, 2025, 08:07 PM
Roche Secures CE Mark For Automated Mass Spectrometry Antibiotics Monitoring Expanding Industry's Broadest In Vitro Diagnostic Menu
📈 PositiveBenzinga•Dec 11, 2025, 07:35 AM
Roche boosts Olema after additional late-stage trial data for breast cancer drug
📈 PositiveSeeking Alpha•Dec 10, 2025, 02:07 PM
Roche Secures European Commission Approval For Gazyva/Gazyvaro In Active Class III Or IV Lupus Nephritis, With Or Without Class V
📈 PositiveBenzinga•Dec 9, 2025, 07:02 AM
Roche Launches PCR Assay Detecting Bacteria And Yeast Linked To BV And Candida Vaginitis With CE Mark Availability
📈 PositiveBenzinga•Dec 9, 2025, 06:55 AM
Roche Receives FDA And CE Mark Approvals For Point Of Care Test Differentiating Multiple Bordetella Infections
📈 PositiveBenzinga•Dec 2, 2025, 06:49 AM
Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials
📈 PositiveSeeking Alpha•Dec 1, 2025, 09:33 AM
Veeva Systems' Veeva Vault CRM Selected By Roche Pharmaceuticals Under Expanded Collaboration
📈 PositiveBenzinga•Nov 24, 2025, 12:18 PM•Also:
Roche Gains Conditional EU Authorization For Lunsumio SC Showing Deep Durable Responses In Third Line Relapsed Or Refractory Follicular Lymphoma
📈 PositiveBenzinga•Nov 19, 2025, 06:32 AM
Olema Pharmaceuticals Shares Trading Higher; Stock Reacts To Roche lidERA Phase 3 Results Demonstrating Superiority Over Aromatase Inhibitors In Early-Breast Cancer, De-Risking SERD Class Development
📈 PositiveBenzinga•Nov 18, 2025, 02:00 PM•Also:
Roche boosts Olema as breast cancer therapy succeeds in late-stage trial
📈 PositiveSeeking Alpha•Nov 18, 2025, 12:00 PM
Roche Reports Unprecedented lidERA Phase III Results Positioning Giredestrant As A Potential New Standard Of Care For ER Positive Early Stage Breast Cancer
📈 PositiveBenzinga•Nov 18, 2025, 06:41 AM
Roche posts late-stage trial wins for new multiple sclerosis therapy
📈 PositiveSeeking Alpha•Nov 10, 2025, 04:40 PM
Roche's Fenebrutinib Delivers Dual Advances Across RMS And PPMS Showing Significant Relapse Reduction And Disability Slowdown Versus Standard Therapies
📈 PositiveBenzinga•Nov 10, 2025, 06:36 AM
Manifold Bio Teams Up With Roche in $2B-Plus AI Drug Discovery Deal
📈 PositiveBenzinga•Nov 3, 2025, 11:48 AM
Roche's Genentech Announces Phase III ALLEGORY Study Results Demonstrating Statistically Significant And Clinically Meaningful Improvement With Gazyva In Systemic Lupus Erythematosus
📈 PositiveBenzinga•Nov 3, 2025, 07:21 AM
Roche Completes Tender Offer For 89bio, Accepts All Validly Tendered Shares At $14.50 Per Share Plus Up To $6.00 In Contingent Payments
📈 PositiveBenzinga•Oct 30, 2025, 06:05 AM•Also:
Frequently Asked Questions about RHHBY
What is RHHBY's current stock price?
Roche Holding AG (RHHBY) is currently trading at $51.20 per share. The stock has moved +1.85% today.
What is the analyst price target for RHHBY?
The average analyst price target for RHHBY is $53.50, based on 1 analyst.
What sector is Roche Holding AG in?
Roche Holding AG operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.
What is RHHBY's market cap?
Roche Holding AG has a market capitalization of $326.25 billion, making it a mega-cap company.
Does RHHBY pay dividends?
No, Roche Holding AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZNCF
AstraZeneca PLC
$181.23
Mkt Cap: $281.0B
CHGCF
Chugai Pharmaceutical Co., Ltd.
$52.65
Mkt Cap: $86.6B
CHGCY
Chugai Pharmaceutical Co., Ltd.
$26.49
Mkt Cap: $87.2B
DSKYF
Daiichi Sankyo Company, Limited
$21.26
Mkt Cap: $39.4B
DSNKY
Daiichi Sankyo Company, Limited
$21.15
Mkt Cap: $39.5B
GLAXF
GSK plc
$24.03
Mkt Cap: $96.8B
NONOF
Novo Nordisk A/S
$48.00
Mkt Cap: $213.4B
NVSEF
Novartis AG
$129.60
Mkt Cap: $248.7B
SNYNF
Sanofi
$95.90
Mkt Cap: $116.8B
SRTOY
Sartorius Stedim Biotech S.A.
$24.29
Mkt Cap: $236.3B
Explore stocks similar to RHHBY for comparison